中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

108 records (took 0.028 seconds)

    FOLLISTATIN-RELATED FUSION PROTEINS AND USES THEREOF
    31.
    发明申请
    FOLLISTATIN-RELATED FUSION PROTEINS AND USES THEREOF 有权
    与相关蛋白相关的融合蛋白及其用途

    公开(公告)号：US20160311874A1

    公开(公告)日：2016-10-27

    申请号：US15081629

    申请日：2016-03-25

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako

    IPC: C07K14/47

    CPC classification number: C07K14/4703 ,  A61K38/00 ,  A61K47/6811 ,  C07K14/4702 ,  C07K19/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/74

    Abstract: In certain aspects, the present disclosure provides compositions and methods for inhibiting activity of TGFβ superfamily ligands, particularly ligands such as GDF8, GDF11, activin A, activin B, activin C and activin E, in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent diseases or disorders that are associated with abnormal activity of a follistatin-related polypeptide and/or a follistatin ligand.

    Abstract translation: 在某些方面，本公开提供了用于抑制TGFβ超家族配体，特别是配体如GDF8，GDF11，激活素A，激活素B，激活素C和激活素E在脊椎动物（包括啮齿动物和灵长类动物）中的活性的组合物和方法，特别是在 人类。 在一些实施方案中，本公开的组合物可用于治疗或预防与卵泡抑素相关多肽和/或卵泡抑素配体的异常活性相关的疾病或病症。

    SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF
    32.
    发明申请
    SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF 审中-公开
    单臂型I型和II型受体融合蛋白及其用途

    公开(公告)号：US20160289298A1

    公开(公告)日：2016-10-06

    申请号：US15092600

    申请日：2016-04-06

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako

    IPC: C07K14/71 ,  C07K16/00

    CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K2319/30

    Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.

    Abstract translation: 在某些方面，本公开提供了包含TGF-β家族的I型丝氨酸/苏氨酸激酶受体的细胞外结构域或TGF-β家族的II型丝氨酸/苏氨酸激酶受体的细胞外结构域的可溶性单臂异聚多肽复合物， beta家族 在一些实施方案中，本公开提供包含选自以下的II型受体的细胞外结构域的可溶性单臂多肽复合物：ActRIIA，ActRIIB，TGFBRII，BMPRII和MISRII。 在一些实施方案中，本公开提供了包含选自以下的I型受体的细胞外结构域的可溶性单臂多肽复合物：ALK1，ALK2，ALK3，ALK4，ALK5，ALK6和ALK7。 任选地，可溶性复合物是异二聚体。 在某些方面，这些可溶性多肽复合物可用于治疗或预防各种TGF-β相关病症，包括但不限于与例如癌症，肌肉，骨骼，脂肪，红细胞，代谢， 纤维化和受TGF-β超家族中一个或多个配体影响的其他组织。

    ALK4:actriib heteromultimers and uses thereof
    34.
    发明授权
    ALK4:actriib heteromultimers and uses thereof 有权

    公开(公告)号：US12258380B2

    公开(公告)日：2025-03-25

    申请号：US17666705

    申请日：2022-02-08

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

    IPC: C07K14/705 ,  C07K14/71

    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

    Variant ActRIIB proteins and uses thereof
    35.
    发明授权
    Variant ActRIIB proteins and uses thereof 有权

    公开(公告)号：US12240887B2

    公开(公告)日：2025-03-04

    申请号：US17687934

    申请日：2022-03-07

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Erik M. Vogan

    IPC: C07K14/71 ,  A61K38/00 ,  A61P21/00

    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

    TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF
    38.
    发明公开
    TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF 审中-公开

    公开(公告)号：US20240158468A1

    公开(公告)日：2024-05-16

    申请号：US18236082

    申请日：2023-08-21

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

    IPC: C07K14/71 ,  A61K38/45 ,  C12N9/12

    CPC classification number: C07K14/71 ,  A61K38/45 ,  C12N9/12 ,  C12Y207/1103 ,  A61K38/00 ,  C07K2319/30

    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

    TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF
    40.
    发明申请
    TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF 有权

    公开(公告)号：US20220396607A1

    公开(公告)日：2022-12-15

    申请号：US16951192

    申请日：2020-11-18

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

    IPC: C07K14/71 ,  A61K38/45 ,  C12N9/12

    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

Patent Agency Ranking